Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu, "Dr. Ion Stoia" Clinical Center for Rheumatic Diseases, Romania, Claudiu C. Popescu, Bogdan Baleanu, Corina Mogosan, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, "Dr. Ion Stoia" Clinical Center for Rheumatic Diseases, Romania, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, Romanian Registry of Rheumatic Diseases, Bucharest, Romania, "Dr. Ion Stoia" Clinical Center for Rheumatic Diseases, Romania, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
2020 Romanian Journal of Rheumatology  
Given the limited resources of the health system, rheumatologists are interested in reducing the costs of modern treatments for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, given that the therapeutic targets are obtained and maintained. Data from the Romanian Registry of Rheumatic Diseases (RRBR, in Romanian) from 2016 to 2019 showed for all three diseases that: continuations on the same regimen with tapering experienced a marked increase; the yearly drug cost per
more » ... drug cost per patient steadily decreased towards 2019; adalimumab and etanercept originators present the most number of administrations per year and consequently the highest afferent costs in the entire observation period; new drugs (biologic biosimilars and targeted synthetic drugs) are gaining specific portions of the market; switches decrease costs of treatment since the hypothetical models in which switches would not have been performed and patients would have continued their previous treatment throughout the respective year showed 11% increases of costs. RRBR data have shown that reaching and maintaining therapeutic targets (including by switching strategies), reducing risks of adverse events by reducing exposure (tapering) and increasing the use of biosimilar biologics lead to significant cost reductions.
doi:10.37897/rjr.2020.1.4 fatcat:3xrxmk7bu5hwrlqnixgpem7dzy